Shareholders' Equity (Tables)

9 Months Ended

Sep. 30, 2023

Stockholders' Equity Note [Abstract]

Summary of comprehensive income (loss)

The following is a summary of comprehensive income (in millions):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2023			2022			2023			2022
Consolidated net income	$	88.7		$	88.4		$	223.9		$	200.2
Foreign currency translation adjustments		(52.2	)		(88.3	)		(16.1	)		(195.7	)
Derivatives designated as hedging instruments, net of tax		21.5			42.9			(5.1	)		105.5
Pension liability adjustments, net of tax		—			1.6			0.8			3.7
Comprehensive income		58.0			44.6			203.5			113.7
Less: Comprehensive income (loss) attributable to    noncontrolling interests		0.3			(0.3	)		2.9			(0.5	)
Less: Comprehensive loss attributable to redeemable    noncontrolling interests		(0.8	)		(0.6	)		(1.1	)		(1.3	)
Comprehensive income attributable to Bruker Corporation	$	58.5		$	45.5		$	201.7		$	115.5

Summary of the components of accumulated other comprehensive income (loss), net of tax

The following is a summary of the components of accumulated other comprehensive income (loss) attributable to Bruker Corporation, net of tax (in millions):

	Foreign Currency Translation			Derivatives Designated as Hedging Instruments			Pension Liability Adjustment		Accumulated Other Comprehensive Income
Balance at December 31, 2022	$	(3.1	)	$	4.1		$	13.8	$	14.8
Other comprehensive income (loss) before    reclassifications		(15.7	)		(5.1	)		0.1		(20.7	)
Realized gain on amounts reclassified from other comprehensive income		—			—			0.7		0.7
Net current period other comprehensive income (loss)		(15.7	)		(5.1	)		0.8		(20.0	)
Balance at September 30, 2023	$	(18.8	)	$	(1.0	)	$	14.6	$	(5.2	)

Schedule of the impact of stock-based compensation expense

The Company recorded stock-based compensation expense as follows in the unaudited condensed consolidated statements of income and comprehensive income (in millions):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Stock options	$	0.4	$	0.3	$	1.2	$	1.1
Restricted stock units		4.2		3.6		11.7		10.4
Employee Stock Purchase Plan		0.2		—		0.6		—
Total stock-based compensation expense	$	4.8	$	3.9	$	13.5	$	11.5

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Cost of product revenue	$	0.4	$	0.2	$	1.1	$	1.0
Selling, general and administrative		3.9		3.3		11.0		9.2
Research and development		0.5		0.4		1.4		1.3
Total stock-based compensation expense	$	4.8	$	3.9	$	13.5	$	11.5